Fortrea Holdings Inc.
NASDAQ:FTRE · NASDAQ Global Select
-$0.07 today
Vol 2.48M · Avg 1.31M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:FTRE · Revenue to Net Income
Key Ratios
Analysis
$2.7B of revenue converted into -$446.9M of net income for the selected period. Gross margin is 16.0% and net margin is -15.9%, showing how much revenue survives after costs and taxes. EPS is $-4.93, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7B +1.0% | $2.7B -5.1% | $2.8B +0.2% | $2.8B -7.2% | $3.1B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.3B +6.3% | $2.2B -4.0% | $2.3B +6.6% | $2.1B -13.9% | $2.5B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $425.8M -20.3% | $534.2M -9.5% | $590.6M -18.5% | $724.4M +19.9% | $604.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 15.6% -4.2pp | 19.8% -1.0pp | 20.8% -4.8pp | 25.5% +5.8pp | 19.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 | $0 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $456.4M -18.6% | $560.7M +25.1% | $448.1M +7.7% | $416.1M +37.3% | $303.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $456.4M -34.4% | $696.1M +24.6% | $558.6M +4.0% | $537.3M +9.6% | $490.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $78.0M -10.2% | $86.9M -11.3% | $98.0M +4.7% | $93.6M -43.7% | $166.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$813.6M -1165.3% | -$64.3M -146.9% | $137.2M -51.1% | $280.8M -7.3% | $302.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -29.9% -27.5pp | -2.4% -7.2pp | 4.8% -5.1pp | 9.9% -0.0pp | 9.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$30.6M +81.1% | -$161.9M -605.9% | $32.0M -82.9% | $187.1M +63.7% | $114.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -1.1% +4.9pp | -6.0% -7.1pp | 1.1% -5.5pp | 6.6% +2.9pp | 3.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $91.4M -26.2% | $123.8M +77.4% | $69.8M +34800.0% | $200.0K +0.0% | $200.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$952.4M -742.1% | -$113.1M -81.0% | -$62.5M -62400.0% | -$100.0K -100.5% | $22.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$983.0M -257.5% | -$275.0M -801.6% | -$30.5M -116.3% | $187.0M +37.1% | $136.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -36.1% -25.9pp | -10.2% -9.1pp | -1.1% -7.7pp | 6.6% +2.1pp | 4.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $3.2M +191.4% | -$3.5M -391.7% | $1.2M -97.1% | $41.1M +7.0% | $38.4M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$986.2M -200.2% | -$328.5M -1203.6% | -$25.2M -113.5% | $186.2M +90.0% | $98.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -36.2% -24.0pp | -12.2% -11.3pp | -0.9% -7.4pp | 6.6% +3.4pp | 3.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$11 -194.6% | -$4 -9075.0% | -$0 -101.9% | $2 +90.1% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$11 -194.6% | -$4 -9075.0% | -$0 -101.9% | $2 +90.1% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $91.2M +1.9% | $89.5M +0.8% | $88.8M +0.5% | $88.4M +0.0% | $88.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $91.2M +1.9% | $89.5M +0.8% | $88.8M +0.5% | $88.4M +0.0% | $88.4M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
AnaptysBio, Inc.
NASDAQ:ANAB
$2.39B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.53B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.48B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.13B
Xencor, Inc.
NASDAQ:XNCR
$928.99M
Kura Oncology, Inc.
NASDAQ:KURA
$852.68M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$850.81M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$736.36M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$610.02M
ProKidney Corp.
NASDAQ:PROK
$262.12M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does FTRE generate?
Fortrea Holdings Inc. (FTRE) reported $2.72B of revenue in fiscal 2025.
Is FTRE profitable?
Fortrea Holdings Inc. (FTRE) reported -$986,200,000.00 of net income, with a net margin of -36.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.